Andere talen Coya Therapeutics, Inc.

Aandelen

COYA

US22407B1089

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,91 ^USD	-2,94%		-9,39%	+6,75%

20/05	Coya Therapeutics ontvangt $5 miljoen aandeleninvestering van Alzheimer's Drug Discovery Foundation	MT
09/05	Coya Therapeutics, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients with Alzheimer's disease	23/05
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease	22/05
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	20/05
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)	20/05
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	17/05
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results	09/05
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	26/04
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit	22/04
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit	18/04
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	08/04
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results	19/03
Coya Therapeutics to Participate in BTIG Fireside Discussion	12/03
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia at the AD/PD 2024 Conference	07/03
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference	06/03
Coya Therapeutics to Present Data on Immune System and Regulatory T cell Contributions in Frontotemporal Dementia Patients at AD/PD 2024 Conference	01/03
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Coya Therapeutics, Inc.

Aandelen

COYA

US22407B1089

Andere talen

Filters